OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile, there is potential to expand OXU-001 development to radiation maculopathy and specifically to radiation-induced macular edema.

OXU-001 are dexamethasone-containing Oxuspheres that are designed to be delivered via Oxulumis to the posterior suprachoroidal space as a highly efficacious, well-tolerated and durable treatment.

In 12-month GLP preclinical studies, OXU-001 was well-tolerated, and related pharmacokinetic data confirmed that therapeutic drug levels were consistently maintained in target retinal tissues. Throughout the study period, only low drug levels were observed in off-target tissues associated with steroid side effects, including the vitreous and lens. This data supports expectations that OXU-001 will provide long-lasting treatment effects, with a meaningfully improved clinical safety profile.

DME patients are likely to have several underlying health issues and are often managed by multiple healthcare professionals. The burden of medical visits for these patients, who are typically of working age, frequently results in missed treatments and suboptimal treatment outcomes. OXU-001 has the potential to address the significant unmet needs of these patients through (i) long treatment durability and significantly fewer injections; (ii) better efficacy through sustained treatment benefits; (iii) better safety through tissue-specific delivery and minimized off-target side effects; and (iv) routine administration through minimally invasive microcatheterization to the suprachoroidal space.

OXU-005 is a potential first-in-class, long-lasting treatment for diabetic retinopathy.

OXU-005 contains a proprietary narrow spectrum kinase inhibitor with potent anti-angiogenic and anti-inflammatory properties. OXU-005 will be prepared using long-lasting Oxuspheres and is designed to be delivered via Oxulumis to the posterior suprachoroidal space. Preclinical studies with OXU-005 demonstrate encouraging efficacy compared to benchmark clinical molecules, with favorable toxicology data supporting human use.

Diabetic retinopathy is a serious, highly prevalent retinal disorder associated with an increased risk of vision-threatening events like retinal neovascularization, bleeding, or retinal edema.

Diabetic retinopathy affects approximately ninety-five million people globally, requiring, in more advanced stages, retinal laser therapy or frequent intravitreal injections and physician visits to prevent permanent vision loss or blindness. OXU-005's benefits significantly address diabetic retinopathy patients' unmet needs for (i) long treatment durability and significantly fewer injections; (ii) better efficacy and risk reduction through sustained treatment effects; (iii) and tissue-specific delivery through minimally invasive microcatheterization to the suprachoroidal space.